Journal of the Formosan Medical Association
Volume 108, Issue 5 , Pages 353-366, May 2009

The Clinical Implications of Blood Adiponectin in Cardiometabolic Disorders

  • Lin-Chau Chang

      Affiliations

    • Graduate Institute of Clinical Medicine, National Taiwan University; Taipei, Taiwan
    • ,
  • Kuo-Chin Huang

      Affiliations

    • Departments of Family Medicine, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Yen-Wen Wu

      Affiliations

    • Departments of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    • Departments of Nuclear Medicine, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Hsien-Li Kao

      Affiliations

    • Department of Medicine, College of Medicine, National Taiwan University; Taipei, Taiwan
    • Departments of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Chi-Ling Chen

      Affiliations

    • Graduate Institute of Clinical Medicine, National Taiwan University; Taipei, Taiwan
    • ,
  • Ling-Ping Lai

      Affiliations

    • Department of Medicine, College of Medicine, National Taiwan University; Taipei, Taiwan
    • Departments of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Juey-Jen Hwang

      Affiliations

    • Department of Medicine, College of Medicine, National Taiwan University; Taipei, Taiwan
    • Departments of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Wei-Shiung Yang

      Affiliations

    • Graduate Institute of Clinical Medicine, National Taiwan University; Taipei, Taiwan
    • Department of Medicine, College of Medicine, National Taiwan University; Taipei, Taiwan
    • Departments of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    • Corresponding Author InformationCorrespondence to: Dr Wei-Shiung Yang, Department of Medicine, College of Medicine, National Taiwan University, 1 Chang-Teh Street, Taipei 100, Taiwan

Received 25 February 2009; received in revised form 28 February 2009; accepted 2 March 2009.

Article Outline

Adipose tissue is now accepted by the scientific and medical community to be a genuine endocrine organ, in addition to its classical role as an energy store. Adiponectin is one of the many adipocytokines that are secreted almost exclusively by adipose tissue. Alteration in blood adiponectin concentrations has been linked to many human diseases in numerous cross-sectional and prospective studies. In this review, we describe briefly the biological effects of adiponectin as revealed by basic scientific investigations. We also summarize the principles of blood adiponectin assays. Overall, lower blood adiponectin concentration is found in subjects with obesity, type 2 diabetes mellitus, dyslipidemia, and hypertension. These medical conditions are components of the metabolic syndrome and major risk factors for accelerated atherosclerosis. Plasma adiponectin levels are also expected to be lower in subjects with cardiovascular diseases, such as coronary artery disease, ischemic stroke and peripheral artery disease. Congestive heart failure (CHF) and cardiac arrhythmia are common end points in cardiovascular diseases. Surprisingly, higher blood adiponectin levels are frequently reported to predict mortality associated with CHF. Few human data regarding adiponectin and cardiac arrhythmia are available. Higher blood adiponectin level has been documented only in atrial fibrillation. We also summarize data on the role of the high molecular weight (HMW) iso-forms of adiponectin and the effects of clinical treatment on the levels of total or HMW adiponectin. Whether adiponectin is a risk marker or a risk factor for the diseases reviewed in this article, and in many other human diseases, and their detailed pathogenic links awaits further investigation.

Key Words:  adiponectin , arrhythmia , atrial fibrillation , cerebrovascular disease , coronary artery disease , diabetes , dyslipidemia , heart failure , hypertension , metabolic syndrome , obesity , peripheral vascular diseases , stroke

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Grundy SM . Metabolic syndrome pandemic . Arterioscler Thromb Vasc Biol . 2008;28:629–636
  2. Hampton T . Scientists study fat as endocrine organ . JAMA . 2006;296:1573–1575
  3. Ingalls AM , Dickie MM , Snell GD . Obese, a new mutation in the house mouse . J Hered . 1950;41:317–318
  4. Hummel KP , Dickie MM , Coleman DL . Diabetes, a new mutation in the mouse . Science . 1966;153:1127–1128
  5. Coleman DL . Obese and diabetes: two mutant genes causing diabetes–obesity syndromes in mice . Diabetologia . 1978;14:141–148
  6. Coleman DL . Effects of parabiosis of obese with diabetes and normal mice . Diabetologia . 1973;9:294–298
  7. Coleman DL , Hummel KP . Effects of parabiosis of normal with genetically diabetic mice . Am J Physiol . 1969;217:1298–1304
  8. Zhang Y , Proenca R , Maffei M , et al.   Positional cloning of the mouse obese gene and its human homologue . Nature . 1994;372:425–432
  9. Halaas JL , Gajiwala KS , Maffei M , et al.   Weight-reducing effects of the plasma protein encoded by the obese gene . Science . 1995;269:543–546
  10. Tartaglia LA , Dembski M , Weng X , et al.   Identification and expression cloning of a leptin receptor, ob-r . Cell . 1995;83:1263–1271
  11. Myers MG , Cowley MA , Munzberg H . Mechanisms of leptin action and leptin resistance . Annu Rev Physiol . 2008;70:537–556
  12. Leinninger GM , Myers MG . Lrb signals act within a distributed network of leptin-responsive neurones to mediate leptin action . Acta Physiol (Oxf) . 2008;192:49–59
  13. Lu JY , Huang KC , Chang LC , et al.   Adiponectin: a biomarker of obesity-induced insulin resistance in adipose tissue and beyond . J Biomed Sci . 2008;15:565–576
  14. Scherer PE , Williams S , Fogliano M , et al.   A novel serum protein similar to c1q, produced exclusively in adipocytes . J Biol Chem . 1995;270:26746–26749
  15. Maeda K , Okubo K , Shimomura I , et al.   Cdna cloning and expression of a novel adipose specific collagen-like factor, apm1 (adipose most abundant gene transcript 1) . Biochem Biophys Res Commun . 1996;221:286–289
  16. Hu E , Liang P , Spiegelman BM . Adipoq is a novel adipose-specific gene dysregulated in obesity . J Biol Chem . 1996;271:10697–10703
  17. Nakano Y , Tobe T , Choi-Miura NH , et al.   Isolation and characterization of gbp28, a novel gelatin-binding protein purified from human plasma . J Biochem (Tokyo) . 1996;120:803–812
  18. Pajvani UB , Du X , Combs TP , et al.   Structure–function studies of the adipocyte-secreted hormone acrp30/adiponectin. Implications for metabolic regulation and bioactivity . J Biol Chem . 2003;278:9073–9085
  19. Magkos F , Sidossis LS . Recent advances in the measurement of adiponectin isoform distribution . Curr Opin Clin Nutr Metab Care . 2007;10:571–575
  20. Waki H , Yamauchi T , Kamon J , et al.   Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin . J Biol Chem . 2003;278:40352–40363
  21. Kobayashi H , Ouchi N , Kihara S , et al.   Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin . Circ Res . 2004;94:e27–e31
  22. Pajvani UB , Hawkins M , Combs TP , et al.   Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity . J Biol Chem . 2004;279:12152–12162
  23. Fruebis J , Tsao TS , Javorschi S , et al.   Proteolytic cleavage product of 30-kda adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice . Proc Natl Acad Sci USA . 2001;98:2005–2010
  24. Berg AH , Combs TP , Du X , et al.   The adipocyte-secreted protein acrp30 enhances hepatic insulin action . Nat Med . 2001;7:947–953
  25. Yamauchi T , Kamon J , Waki H , et al.   The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity . Nat Med . 2001;7:941–946
  26. Combs TP , Berg AH , Obici S , et al.   Endogenous glucose production is inhibited by the adipose-derived protein acrp30 . J Clin Invest . 2001;108:1875–1881
  27. Kubota N , Terauchi Y , Yamauchi T , et al.   Disruption of adiponectin causes insulin resistance and neointimal formation . J Biol Chem . 2002;277:25863–25866
  28. Maeda N , Shimomura I , Kishida K , et al.   Diet-induced insulin resistance in mice lacking adiponectin/acrp30 . Nat Med . 2002;8:731–737
  29. Yamauchi T , Kamon J , Waki H , et al.   Globular adiponectin protected ob/ob mice from diabetes and apoE-deficient mice from atherosclerosis . J Biol Chem . 2003;278:2461–2468
  30. Ohashi K , Kihara S , Ouchi N , et al.   Adiponectin replenishment ameliorates obesity-related hypertension . Hypertension . 2006;47:1108–1116
  31. Shibata R , Ouchi N , Ito M , et al.   Adiponectin-mediated modulation of hypertrophic signals in the heart . Nat Med . 2004;10:1384–1389
  32. Okamoto Y , Kihara S , Ouchi N , et al.   Adiponectin reduces atherosclerosis in apolipoprotein e-deficient mice . Circulation . 2002;106:2767–2770
  33. Matsuda M , Shimomura I , Sata M , et al.   Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis . J Biol Chem . 2002;277:37487–37491
  34. Kato H , Kashiwagi H , Shiraga M , et al.   Adiponectin acts as an endogenous antithrombotic factor . Arterioscler Thromb Vasc Biol . 2006;26:224–230
  35. Shibata R , Ouchi N , Kihara S , et al.   Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of amp-activated protein kinase signaling . J Biol Chem . 2004;279:28670–28674
  36. Yamauchi T , Kamon J , Ito Y , et al.   Cloning of adiponectin receptors that mediate antidiabetic metabolic effects . Nature . 2003;423:762–769
  37. Yamauchi T , Nio Y , Maki T , et al.   Targeted disruption of adipor1 and adipor2 causes abrogation of adiponectin binding and metabolic actions . Nat Med . 2007;13:332–339
  38. Luo XH , Guo LJ , Yuan LQ , et al.   Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway . Exp Cell Res . 2005;309:99–109
  39. Wu X , Mahadev K , Fuchsel L , et al.   Adiponectin suppresses IkappaB kinase activation induced by tumor necrosis factor-alpha or high glucose in endothelial cells: role of camp and amp kinase signaling . Am J Physiol Endocrinol Metab . 2007;293:E1836–E1844
  40. Chen H , Montagnani M , Funahashi T , et al.   Adiponectin stimulates production of nitric oxide in vascular endothelial cells . J Biol Chem . 2003;278:45021–45026
  41. Kadowaki T , Yamauchi T , Kubota N . The physiological and pathophysiological role of adiponectin and adiponectin receptors in the peripheral tissues and CNS . FEBS Lett . 2008;582:74–80
  42. Arita Y , Kihara S , Ouchi N , et al.   Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity . Biochem Biophys Res Commun . 1999;257:79–83
  43. Ebinuma H , Miyazaki O , Yago H , et al.   A novel ELISA system for selective measurement of human adiponectin multimers by using proteases . Clin Chim Acta . 2006;372:47–53
  44. Nakano Y , Tajima S , Yoshimi A , et al.   A novel enzyme-linked immunosorbent assay specific for high-molecular-weight adiponectin . J Lipid Res . 2006;47:1572–1582
  45. Ebinuma H , Miida T , Yamauchi T , et al.   Improved ELISA for selective measurement of adiponectin multimers and identification of adiponectin in human cerebrospinal fluid . Clin Chem . 2007;53:1541–1544
  46. Tanita T , Miyakoshi H , Nakano Y . Performance of ELISA for specific measurement of high-molecular-weight (HMW) adiponectin . J Immunol Methods . 2008;333:139–146
  47. Sinha MK , Songer T , Xiao Q , et al.   Analytical validation and biological evaluation of a high molecular-weight adiponectin ELISA . Clin Chem . 2007;53:2144–2151
  48. Glintborg D , Frystyk J , Hojlund K , et al.   Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo-controlled study in polycystic ovary syndrome . Clin Endocrinol (Oxf) . 2008;68:165–174
  49. Rogers CQ , Ajmo JM , You M . Adiponectin and alcoholic fatty liver disease . IUBMB Life . 2008;60:790–797
  50. Gualillo O , Gonzalez-Juanatey JR , Lago F . The emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspectives . Trends Cardiovasc Med . 2007;17:275–283
  51. Kelesidis I , Kelesidis T , Mantzoros CS . Adiponectin and cancer: a systematic review . Br J Cancer . 2006;94:1221–1225
  52. Yang WS , Chuang LM . Human genetics of adiponectin in the metabolic syndrome . J Mol Med . 2006;84:112–121
  53. Menzaghi C , Trischitta V , Doria A . Genetic influences of adiponectin on insulin resistance, type 2 diabetes, and cardiovascular disease . Diabetes . 2007;56:1198–1209
  54. Crimmins NA , Woo JG , Kaushal RD , et al.   Adiponectin receptor 1 variants associated with lower insulin resistance in African Americans . Obesity . 2007;15:1903–1907
  55. Cnop M , Havel PJ , Utzschneider KM , et al.   Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex . Diabetologia . 2003;46:459–469
  56. Yatagai T , Nagasaka S , Taniguchi A , et al.   Hypoadiponectinemia is associated with visceral fat accumulation and insulin resistance in Japanese men with type 2 diabetes mellitus . Metabolism . 2003;52:1274–1278
  57. Staiger H , Tschritter O , Machann J , et al.   Relationship of serum adiponectin and leptin concentrations with body fat distribution in humans . Obes Res . 2003;11:368–372
  58. Vozarova B , Stefan N , Lindsay RS , et al.   Low plasma adiponectin concentrations do not predict weight gain in humans . Diabetes . 2002;51:2964–2967
  59. Hotta K , Funahashi T , Arita Y , et al.   Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients . Arterioscler Thromb Vasc Biol . 2000;20:1595–1599
  60. Hulver MW , Zheng D , Tanner CJ , et al.   Adiponectin is not altered with exercise training despite enhanced insulin action . Am J Physiol Endocrinol Metab . 2002;283:E861–E865
  61. Yatagai T , Nishida Y , Nagasaka S , et al.   Relationship between exercise training-induced increase in insulin sensitivity and adiponectinemia in healthy men . Endocr J . 2003;50:233–238
  62. Valsamakis G , McTernan PG , Chetty R , et al.   Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines . Metabolism . 2004;53:430–434
  63. Hsieh CJ , Wang PW , Liu RT , et al.   Orlistat for obesity: benefits beyond weight loss . Diabetes Res Clin Pract . 2005;67:78–83
  64. Kim DM , Yoon SJ , Ahn CW , et al.   Sibutramine improves fat distribution and insulin resistance, and increases serum adiponectin levels in Korean obese nondiabetic premenopausal women . Diabetes Res Clin Pract . 2004;66(Suppl 1):S139–S144
  65. Hung YJ , Chen YC , Pei D , et al.   Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with type 2 diabetes . Diabet Med . 2005;22:1024–1030
  66. Despres JP , Golay A , Sjostrom L . Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia . N Engl J Med . 2005;353:2121–2134
  67. Calvani M , Scarfone A , Granato L , et al.   Restoration of adiponectin pulsatility in severely obese subjects after weight loss . Diabetes . 2004;53:939–947
  68. Yang WS , Lee WJ , Funahashi T , et al.   Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin . J Clin Endocrinol Metab . 2001;86:3815–3819
  69. Klein S , Fontana L , Young VL , et al.   Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease . N Engl J Med . 2004;350:2549–2557
  70. Giugliano G , Nicoletti G , Grella E , et al.   Effect of liposuction on insulin resistance and vascular inflammatory markers in obese women . Br J Plast Surg . 2004;57:190–194
  71. Nakatani H , Hirose H , Yamamoto Y , et al.   Significance of leptin and high-molecular weight adiponectin in the general population of Japanese male adolescents . Metabolism . 2008;57:157–162
  72. Kaser S , Tatarczyk T , Stadlmayr A , et al.   Effect of obesity and insulin sensitivity on adiponectin isoform distribution . Eur J Clin Invest . 2008;38:827–834
  73. Schober F , Neumeier M , Weigert J , et al.   Low molecular weight adiponectin negatively correlates with the waist circumference and monocytic IL-6 release . Biochem Biophys Res Commun . 2007;361:968–973
  74. Bobbert T , Rochlitz H , Wegewitz U , et al.   Changes of adiponectin oligomer composition by moderate weight reduction . Diabetes . 2005;54:2712–2719
  75. Engl J , Bobbert T , Ciardi C , et al.   Effects of pronounced weight loss on adiponectin oligomer composition and metabolic parameters . Obesity (Silver Spring) . 2007;15:1172–1178
  76. Weyer C , Funahashi T , Tanaka S , et al.   Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia . J Clin Endocrinol Metab . 2001;86:1930–1935
  77. Yang WS , Lee WJ , Funahashi T , et al.   Plasma adiponectin levels in overweight and obese Asians . Obes Res . 2002;10:1104–1110
  78. Lindsay RS , Funahashi T , Hanson RL , et al.   Adiponectin and development of type 2 diabetes in the Pima Indian population . Lancet . 2002;360:57–58
  79. Daimon M , Oizumi T , Saitoh T , et al.   Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese population: the Funagata study . Diabetes Care . 2003;26:2015–2020
  80. Snehalatha C , Mukesh B , Simon M , et al.   Plasma adiponectin is an independent predictor of type 2 diabetes in Asian Indians . Diabetes Care . 2003;26:3226–3229
  81. Stefan N , Vozarova B , Funahashi T , et al.   Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans . Diabetes . 2002;51:1884–1888
  82. Yamamoto Y , Hirose H , Saito I , et al.   Adiponectin, an adipocyte-derived protein, predicts future insulin resistance: two-year follow-up study in Japanese population . J Clin Endocrinol Metab . 2004;89:87–90
  83. Duncan BB , Schmidt MI , Pankow JS , et al.   Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study . Diabetes . 2004;53:2473–2478
  84. Snijder MB , Heine RJ , Seidell JC , et al.   Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and women: the Hoorn study . Diabetes Care . 2006;29:2498–2503
  85. Mather KJ , Funahashi T , Matsuzawa Y , et al.   Adiponectin, change in adiponectin, and progression to diabetes in the diabetes prevention program . Diabetes . 2008;57:980–986
  86. Hara K , Horikoshi M , Yamauchi T , et al.   Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome . Diabetes Care . 2006;29:1357–1362
  87. Nakashima R , Kamei N , Yamane K , et al.   Decreased total and high molecular weight adiponectin are independent risk factors for the development of type 2 diabetes in Japanese-Americans . J Clin Endocrinol Metab . 2006;91:3873–3877
  88. Basu R , Pajvani UB , Rizza RA , et al.   Selective downregulation of the high-molecular weight form of adiponectin in hyperinsulinemia and in type 2 diabetes. Differential regulation from nondiabetic subjects . Diabetes . 2007;56:2174–2177
  89. Seino Y , Hirose H , Saito I , et al.   High molecular weight multimer form of adiponectin as a useful marker to evaluate insulin resistance and metabolic syndrome in Japanese men . Metabolism . 2007;56:1493–1499
  90. Imagawa A , Funahashi T , Nakamura T , et al.   Elevated serum concentration of adipose-derived factor, adiponectin, in patients with type 1 diabetes . Diabetes Care . 2002;25:1665–1666
  91. Celi F , Bini V , Papi F , et al.   Circulating adipocytokines in non-diabetic and type 1 diabetic children: relationship to insulin therapy, glycaemic control and pubertal development . Diabet Med . 2006;23:660–665
  92. Frystyk J , Tarnow L , Hansen TK , et al.   Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications . Diabetologia . 2005;48:1911–1918
  93. Galler A , Gelbrich G , Kratzsch J , et al.   Elevated serum levels of adiponectin in children, adolescents and young adults with type 1 diabetes and the impact of age, gender, body mass index and metabolic control: a longitudinal study . Eur J Endocrinol . 2007;157:481–489
  94. Leth H , Andersen KK , Frystyk J , et al.   Elevated levels of high-molecular-weight adiponectin in type 1 diabetes . J Clin Endocrinol Metab . 2008;93:3186–3191
  95. Truyen I , De Grijse J , Van Schravendijk C , et al.   Adiponectin levels do not predict clinical onset of type 1 diabetes in antibody-positive relatives . Diabetologia . 2007;50:2143–2146
  96. Schaffler A , Herfarth H , Paul G , et al.   Identification of influencing variables on adiponectin serum levels in diabetes mellitus type 1 and type 2 . Exp Clin Endocrinol Diabetes . 2004;112:383–389
  97. Schalkwijk CG , Chaturvedi N , Schram MT , et al.   Adiponectin is inversely associated with renal function in type 1 diabetic patients . J Clin Endocrinol Metab . 2006;91:129–135
  98. Saraheimo M , Forsblom C , Thorn L , et al.   Serum adiponectin and progression of diabetic nephropathy in patients with type 1 diabetes . Diabetes Care . 2008;31:1165–1169
  99. Barnes MM , Curran-Everett D , Hamman RF , et al.   Determinants of adiponectin levels in young people with type 1 diabetes . Diabet Med . 2008;25:365–369
  100. Balagopal P , George D , Yarandi H , et al.   Reversal of obesity-related hypoadiponectinemia by lifestyle intervention: a controlled, randomized study in obese adolescents . J Clin Endocrinol Metab . 2005;90:6192–6197
  101. Yang WS , Jeng CY , Wu TJ , et al.   Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients . Diabetes Care . 2002;25:376–380
  102. Putz DM , Goldner WS , Bar RS , et al.   Adiponectin and C-reactive protein in obesity, type 2 diabetes, and monodrug therapy . Metabolism . 2004;53:1454–1461
  103. Nagasaka S , Taniguchi A , Aiso Y , et al.   Effect of glimepiride on serum adiponectin level in subjects with type 2 diabetes . Diabetes Care . 2003;26:2215–2216
  104. Tsunekawa T , Hayashi T , Suzuki Y , et al.   Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects . Diabetes Care . 2003;26:285–289
  105. Muller G . The molecular mechanism of the insulinmimetic/sensitizing activity of the antidiabetic sulfonylurea drug amaryl . Mol Med . 2000;6:907–933
  106. Lund SS , Tarnow L , Stehouwer CD , et al.   Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial . Diabetes Obes Metab . 2007;9:394–407
  107. Spranger J , Mohlig M , Wegewitz U , et al.   Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome . Clin Endocrinol (Oxf) . 2004;61:738–746
  108. Rasouli N , Yao-Borengasser A , Miles LM , et al.   Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression . Am J Physiol Endocrinol Metab . 2006;290:E42–E46
  109. Ochiai H , Ooka H , Shida C , et al.   Acarbose treatment increases serum total adiponectin levels in patients with type 2 diabetes . Endocr J . 2008;55:549–556
  110. Hirose H , Kawai T , Yamamoto Y , et al.   Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes . Metabolism . 2002;51:314–317
  111. Qurashi S , Mynarcik DC , McNurlan MA , et al.   Importance of the high-molecular-mass isoform of adiponectin in improved insulin sensitivity with rosiglitazone treatment in HIV disease . Clin Sci (Lond) . 2008;115:197–202
  112. Tonelli J , Li W , Kishore P , et al.   Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes . Diabetes . 2004;53:1621–1629
  113. Pfutzner A , Lorra B , Abdollahnia MR , et al.   The switch from sulfonylurea to preprandial short-acting insulin analog substitution has an immediate and comprehensive beta-cell protective effect in patients with type 2 diabetes mellitus . Diabetes Technol Ther . 2006;8:375–384
  114. Miyashita Y , Nishimura R , Nemoto M , et al.   Prospective randomized study for optimal insulin therapy in type 2 diabetic patients with secondary failure . Cardiovasc Diabetol . 2008;7:16
  115. Juurinen L , Tiikkainen M , Hakkinen AM , et al.   Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes . Am J Physiol Endocrinol Metab . 2007;292:E829–E835
  116. Mohlig M , Wegewitz U , Osterhoff M , et al.   Insulin decreases human adiponectin plasma levels . Horm Metab Res . 2002;34:655–658
  117. Dullaart RP , Riemens SC , Meinardi JR , et al.   Plasma adiponectin is modestly decreased during 24-hour insulin infusion but not after inhibition of lipolysis by acipimox . Scand J Clin Lab Invest . 2005;65:523–531
  118. Brame LA , Considine RV , Yamauchi M , et al.   Insulin and endothelin in the acute regulation of adiponectin in vivo in humans . Obes Res . 2005;13:582–588
  119. Blumer RM , van der Crabben SN , Stegenga ME , et al.   Hyperglycemia prevents the suppressive effect of hyperinsulinemia on plasma adiponectin levels in healthy humans . Am J Physiol Endocrinol Metab . 2008;295:E613–E617
  120. Krusinova E , Klementova M , Kopecky J , et al.   Effect of acute hyperinsulinaemia with and without angiotensin II type 1 receptor blockade on resistin and adiponectin concentrations and expressions in healthy subjects . Eur J Endocrinol . 2007;157:443–449
  121. Matsubara M , Maruoka S , Katayose S . Decreased plasma adiponectin concentrations in women with dyslipidemia . J Clin Endocrinol Metab . 2002;87:2764–2769
  122. Huang KC , Lue BH , Yen RF , et al.   Plasma adiponectin levels and metabolic factors in nondiabetic adolescents . Obes Res . 2004;12:119–124
  123. Schulze MB , Rimm EB , Shai I , et al.   Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes . Diabetes Care . 2004;27:1680–1687
  124. Kazumi T , Kawaguchi A , Hirano T , et al.   Serum adiponectin is associated with high-density lipoprotein cholesterol, triglycerides, and low-density lipoprotein particle size in young healthy men . Metabolism . 2004;53:589–593
  125. Lara-Castro C , Luo N , Wallace P , et al.   Adiponectin multimeric complexes and the metabolic syndrome trait cluster . Diabetes . 2006;55:249–259
  126. Koh KK , Quon MJ , Han SH , et al.   Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients . Circulation . 2004;110:3687–3692
  127. Bayes B , Granada ML , Lauzurica R , et al.   Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients . Transplant Proc . 2005;37:3808–3812
  128. Gannage-Yared MH , Azar RR , Amm-Azar M , et al.   Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients . Metabolism . 2005;54:947–951
  129. Sonmez A , Dogru T , Tasci I , et al.   The effect of fluvastatin on plasma adiponectin levels in dyslipidaemia . Clin Endocrinol (Oxf) . 2006;64:567–572
  130. Gouni-Berthold I , Berthold HK , Chamberland JP , et al.   Short-term treatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy men . Clin Endocrinol (Oxf) . 2008;68:536–541
  131. Koh KK , Quon MJ , Han SH , et al.   Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients . Diabetes Care . 2006;29:195–201
  132. Rosenson RS . Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients . Obesity (Silver Spring) . 2009;17:504–509
  133. Asano A , Kobayashi J , Murase Y , et al.   Effects of fenofibrate therapy on plasma ubiquinol-10 and ubiquinone-10 levels in Japanese patients with hyperlipidemia and type 2 diabetes mellitus . Pharmacotherapy . 2006;26:447–451
  134. Otto C , Otto B , Frost RJ , et al.   Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia . Acta Diabetol . 2007;44:65–68
  135. Oki K , Koide J , Nakanishi S , et al.   Fenofibrate increases high molecular weight adiponectin in subjects with hypertriglyceridemia . Endocr J . 2007;54:431–435
  136. Westphal S , Borucki K , Taneva E , et al.   Extended-release niacin raises adiponectin and leptin . Atherosclerosis . 2007;193:361–365
  137. Plaisance EP , Grandjean PW , Brunson BL , et al.   Increased total and high-molecular weight adiponectin after extended-release niacin . Metabolism . 2008;57:404–409
  138. Westphal S , Luley C . Preferential increase in high-molecular weight adiponectin after niacin . Atherosclerosis . 2008;198:179–183
  139. Bajaj M , Suraamornkul S , Kashyap S , et al.   Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes . J Clin Endocrinol Metab . 2004;89:4649–4655
  140. Bajaj M , Suraamornkul S , Romanelli A , et al.   Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty acyl-CoAs and insulin action in type 2 diabetic patients . Diabetes . 2005;54:3148–3153
  141. Bernstein EL , Koutkia P , Ljungquist K , et al.   Acute regulation of adiponectin by free fatty acids . Metabolism . 2004;53:790–793
  142. Kazumi T , Kawaguchi A , Sakai K , et al.   Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure . Diabetes Care . 2002;25:971–976
  143. Dzielinska Z , Januszewicz A , Wiecek A , et al.   Decreased plasma concentration of a novel anti-inflammatory protein–adiponectin–in hypertensive men with coronary artery disease . Thromb Res . 2003;110:365–369
  144. Huang KC , Chen CL , Chuang LM , et al.   Plasma adiponectin levels and blood pressures in nondiabetic adolescent females . J Clin Endocrinol Metab . 2003;88:4130–4134
  145. Adamczak M , Wiecek A , Funahashi T , et al.   Decreased plasma adiponectin concentration in patients with essential hypertension . Am J Hypertens . 2003;16:72–75
  146. Chow WS , Cheung BM , Tso AW , et al.   Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year prospective study . Hypertension . 2007;49:1455–1461
  147. Koh KK , Quon MJ , Han SH , et al.   Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs . Int J Cardiol . 2008 Dec 5; [Epub ahead of print]
  148. Piecha G , Adamczak M , Chudek J , et al.   Indapamide decreases plasma adiponectin concentration in patients with essential hypertension . Kidney Blood Press Res . 2007;30:187–194
  149. Yilmaz MI , Sonmez A , Caglar K , et al.   Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome . Nephrology (Carlton) . 2007;12:147–153
  150. Benndorf RA , Rudolph T , Appel D , et al.   Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension . Metabolism . 2006;55:1159–1164
  151. Koh KK , Han SH , Ahn JY , et al.   Amlodipine improves endothelial function and metabolic parameters in patients with hypertension . Int J Cardiol . 2009;133:23–31
  152. Furuhashi M , Ura N , Higashiura K , et al.   Blockade of the renin–angiotensin system increases adiponectin concentrations in patients with essential hypertension . Hypertension . 2003;42:76–81
  153. Koh KK , Quon MJ , Han SH , et al.   Anti-inflammatory and metabolic effects of candesartan in hypertensive patients . Int J Cardiol . 2006;108:96–100
  154. Delles C , Raff U , Mimran A , et al.   Effects of telmisartan and ramipril on adiponectin and blood pressure in patients with type 2 diabetes . Am J Hypertens . 2008;21:1330–1336
  155. Matsumoto S , Takebayashi K , Aso Y . The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy . Metabolism . 2006;55:1645–1652
  156. Uchida T , Shimizu M , Sakai Y , et al.   Effects of losartan on serum total and high-molecular weight adiponectin concentrations in hypertensive patients with metabolic syndrome . Metabolism . 2008;57:1278–1285
  157. Ouchi N , Kihara S , Arita Y , et al.   Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin . Circulation . 1999;100:2473–2476
  158. Kumada M , Kihara S , Sumitsuji S , et al.   Association of hypoadiponectinemia with coronary artery disease in men . Arterioscler Thromb Vasc Biol . 2003;23:85–89
  159. Nakamura Y , Shimada K , Fukuda D , et al.   Implications of plasma concentrations of adiponectin in patients with coronary artery disease . Heart . 2004;90:528–533
  160. Pilz S , Maerz W , Weihrauch G , et al.   Adiponectin serum concentrations in men with coronary artery disease: the LUdwigshafen RIsk and Cardiovascular Health (LURIC) study . Clin Chim Acta . 2006;364:251–255
  161. Lu G , Chiem A , Anuurad E , et al.   Adiponectin levels are associated with coronary artery disease across Caucasian and African-American ethnicity . Transl Res . 2007;149:317–323
  162. Costacou T , Zgibor JC , Evans RW , et al.   The prospective association between adiponectin and coronary artery disease among individuals with type 1 diabetes. The Pittsburgh epidemiology of diabetes complications study . Diabetologia . 2005;48:41–48
  163. Schnabel R , Messow CM , Lubos E , et al.   Association of adiponectin with adverse outcome in coronary artery disease patients: results from the atherogene study . Eur Heart J . 2008;29:649–657
  164. Takemoto F , Katori H , Sawa N , et al.   Plasma adiponectin: a predictor of coronary heart disease in hemodialysis patients–a Japanese prospective eight-year study . Nephron Clin Pract . 2008;111:c12–c20
  165. Lim S , Koo BK , Cho SW , et al.   Association of adiponectin and resistin with cardiovascular events in Korean patients with type 2 diabetes: the Korean Atherosclerosis Study (KAS): a 42-month prospective study . Atherosclerosis . 2008;196:398–404
  166. Cavusoglu E , Ruwende C , Chopra V , et al.   Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain . Eur Heart J . 2006;27:2300–2309
  167. Pischon T , Girman CJ , Hotamisligil GS , et al.   Plasma adiponectin levels and risk of myocardial infarction in men . JAMA . 2004;291:1730–1737
  168. Lawlor DA , Davey Smith G , Ebrahim S , et al.   Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women . J Clin Endocrinol Metab . 2005;90:5677–5683
  169. Soderberg S , Colquhoun D , Keech A , et al.   Leptin, but not adiponectin, is a predictor of recurrent cardiovascular events in men: results from the lipid study . Int J Obes (Lond) . 2009;33:123–130
  170. Sattar N , Wannamethee G , Sarwar N , et al.   Adiponectin and coronary heart disease: a prospective study and metaanalysis . Circulation . 2006;114:623–629
  171. Aso Y , Yamamoto R , Wakabayashi S , et al.   Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin . Diabetes . 2006;55:1954–1960
  172. Inoue T , Kotooka N , Morooka T , et al.   High molecular weight adiponectin as a predictor of long-term clinical outcome in patients with coronary artery disease . Am J Cardiol . 2007;100:569–574
  173. von Eynatten M , Humpert PM , Bluemm A , et al.   Highmolecular weight adiponectin is independently associated with the extent of coronary artery disease in men . Atherosclerosis . 2008;199:123–128
  174. Rizza S , Clementi F , Porzio O , et al.   Adiponectin isoforms are not associated with the severity of coronary atherosclerosis but with undiagnosed diabetes in patients affected by stable CAD . Nutr Metab Cardiovasc Dis . 2009;19:54–60
  175. von Eynatten M , Hamann A , Twardella D , et al.   Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease . Eur Heart J . 2008;29:1307–1315
  176. Sattar N , Watt P , Cherry L , et al.   High molecular weight adiponectin is not associated with incident coronary heart disease in older women: a nested prospective case-control study . J Clin Endocrinol Metab . 2008;93:1846–1849
  177. Hwang JJ , Yang WS , Chiang FT , et al.   Association of circulating matrix metalloproteinase-1, but not adiponectin, with advanced coronary artery disease . Atherosclerosis . 2008 Aug 28; [Epub ahead of print]
  178. Chen MP , Tsai JC , Chung FM , et al.   Hypoadiponectinemia is associated with ischemic cerebrovascular disease . Arterioscler Thromb Vasc Biol . 2005;25:821–826
  179. Efstathiou SP , Tsioulos DI , Tsiakou AG , et al.   Plasma adiponectin levels and five-year survival after first-ever ischemic stroke . Stroke . 2005;36:1915–1919
  180. Soderberg S , Stegmayr B , Stenlund H , et al.   Leptin, but not adiponectin, predicts stroke in males . J Intern Med . 2004;256:128–136
  181. Matsumoto M , Ishikawa S , Kajii E . Association of adiponectin with cerebrovascular disease: a nested case-control study . Stroke . 2008;39:323–328
  182. Stott DJ , Welsh P , Rumley A , et al.   Adipocytokines and risk of stroke in older people: a nested case-control study . Int J Epidemiol . 2009;38:253–261
  183. Lim PS , Hu CY , Wu MY , et al.   Plasma adiponectin is associated with ankle-brachial index in patients on haemodialysis . Nephrology (Carlton) . 2007;12:546–552
  184. Kokubu N , Tsuchihashi K , Yuda S , et al.   Persistent insulin-sensitizing effects of sarpogrelate hydrochloride, a serotonin 2a receptor antagonist, in patients with peripheral arterial disease . Circ J . 2006;70:1451–1456
  185. Kistorp C , Faber J , Galatius S , et al.   Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure . Circulation . 2005;112:1756–1762
  186. George J , Patal S , Wexler D , et al.   Circulating adiponectin concentrations in patients with congestive heart failure . Heart . 2006;92:1420–1424
  187. Wannamethee SG , Whincup PH , Lennon L , et al.   Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure . Arch Intern Med . 2007;167:1510–1517
  188. Tamura T , Furukawa Y , Taniguchi R , et al.   Serum adiponectin level as an independent predictor of mortality in patients with congestive heart failure . Circ J . 2007;71:623–630
  189. Haugen E , Furukawa Y , Isic A , et al.   Increased adiponectin level in parallel with increased NT-pro BNP in patients with severe heart failure in the elderly: a hospital cohort study . Int J Cardiol . 2008;125:216–219
  190. Norrelund H , Wiggers H , Halbirk M , et al.   Abnormalities of whole body protein turnover, muscle metabolism and levels of metabolic hormones in patients with chronic heart failure . J Intern Med . 2006;260:11–21
  191. McEntegart MB , Awede B , Petrie MC , et al.   Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and b-type natriuretic peptide . Eur Heart J . 2007;28:829–835
  192. Ingelsson E , Riserus U , Berne C , et al.   Adiponectin and risk of congestive heart failure . JAMA . 2006;295:1772–1774
  193. Tsutamoto T , Tanaka T , Sakai H , et al.   Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure . Eur Heart J . 2007;28:1723–1730
  194. Komaba H , Igaki N , Goto S , et al.   Adiponectin is associated with brain natriuretic peptide and left ventricular hypertrophy in hemodialysis patients with type 2 diabetes mellitus . Nephron Clin Pract . 2007;107:c103–c108
  195. von Eynatten M , Hamann A , Twardella D , et al.   Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia, and heart failure in patients with coronary heart disease . Clin Chem . 2006;52:853–859
  196. Tanaka T , Tsutamoto T , Sakai H , et al.   Effect of atrial natriuretic peptide on adiponectin in patients with heart failure . Eur J Heart Fail . 2008;10:360–366
  197. Shimano M , Shibata R , Tsuji Y , et al.   Circulating adiponectin levels in patients with atrial fibrillation . Circ J . 2008;72:1120–1124

PII: S0929-6646(09)60079-6

doi:10.1016/S0929-6646(09)60079-6

Journal of the Formosan Medical Association
Volume 108, Issue 5 , Pages 353-366, May 2009

Article Tools